Pilot Study of Rituximab and Brentuximab Vedotin With Deferred BMT for Relapsed Classical Hodgkin Lymphoma

Trial Profile

Pilot Study of Rituximab and Brentuximab Vedotin With Deferred BMT for Relapsed Classical Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 30 May 2016

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Rituximab (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 May 2016 Brentuximab vedotin will be given for up to 10 doses (cycles) instead of 8 doses (cycles).
    • 06 Jul 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 24 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top